AbCellera Biologics (ABCL) Hisse Özeti
AbCellera Biologics Inc. Amerika Birleşik Devletleri'nde karşılanmamış tıbbi ihtiyacı olan endikasyonlar için antikor bazlı ilaçların keşfedilmesi ve geliştirilmesiyle ilgilenmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 0/6 |
| Gelecekteki Büyüme | 1/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
ABCL Community Fair Values
Create NarrativeSee what 99 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AbCellera Biologics Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$8.11 |
| 52 Haftanın En Yüksek Seviyesi | US$8.42 |
| 52 Haftanın En Düşük Seviyesi | US$2.75 |
| Beta | 1.15 |
| 1 Aylık Değişim | 44.31% |
| 3 Aylık Değişim | 145.76% |
| 1 Yıllık Değişim | 101.24% |
| 3 Yıllık Değişim | 19.44% |
| 5 Yıllık Değişim | -56.51% |
| Halka arzdan bu yana değişim | -86.23% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jun 25
ABCL: Menopause Phase 2 Progress Will Shape Future Upside Potential
Analysts have lifted their price target on AbCellera Biologics by $1, citing recent bullish coverage and views that the company’s profile compares favorably with certain peers as key reasons for the change. Analyst Commentary Recent research on AbCellera Biologics points to a generally positive tone, with several bullish initiations and a modest price target increase that together shape how analysts are thinking about the stock’s valuation, growth potential, and execution risks.Seeking Alpha • Jun 17
AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its Cash
Summary AbCellera, an antibody platform behind two authorized COVID-19 therapies, has rebuilt itself into a clinical-stage biotech and is one quarter away from pivotal Phase 2 data on its first wholly-owned. The deeper story is the platform: an integrated, AI-driven discovery engine that mines millions of immune cells rather than designing molecules from scratch, backed by a decade of proprietary wet lab. With more than $650M in liquidity against a roughly $1.6B market cap, investors are paying little more than cash and effectively getting the platform, the pipeline, and ~100 royalty positions. I initiate my coverage of AbCellera with a “Buy” rating, viewing it as an asymmetric, catalyst-driven bet for investors who can tolerate binary risk. Read the full article on Seeking AlphaRecent updates
Anlatı Güncellemesi • Jun 25
ABCL: Menopause Phase 2 Progress Will Shape Future Upside Potential
Analysts have lifted their price target on AbCellera Biologics by $1, citing recent bullish coverage and views that the company’s profile compares favorably with certain peers as key reasons for the change. Analyst Commentary Recent research on AbCellera Biologics points to a generally positive tone, with several bullish initiations and a modest price target increase that together shape how analysts are thinking about the stock’s valuation, growth potential, and execution risks.Seeking Alpha • Jun 17
AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its Cash
Summary AbCellera, an antibody platform behind two authorized COVID-19 therapies, has rebuilt itself into a clinical-stage biotech and is one quarter away from pivotal Phase 2 data on its first wholly-owned. The deeper story is the platform: an integrated, AI-driven discovery engine that mines millions of immune cells rather than designing molecules from scratch, backed by a decade of proprietary wet lab. With more than $650M in liquidity against a roughly $1.6B market cap, investors are paying little more than cash and effectively getting the platform, the pipeline, and ~100 royalty positions. I initiate my coverage of AbCellera with a “Buy” rating, viewing it as an asymmetric, catalyst-driven bet for investors who can tolerate binary risk. Read the full article on Seeking AlphaAnlatı Güncellemesi • Jun 10
ABCL: Menopause Phase 2 Progress Will Support Future Margin Expansion
The analyst price target on AbCellera Biologics has been raised by $1. Analysts cite updated fair value estimates, a slightly lower discount rate, revised revenue growth expectations, and a very large projected future P/E multiple as key drivers of the change.
Anlatı Güncellemesi • May 26
ABCL: GPCR Platform Progress And Upcoming Women’s Health Data Will Drive Upside
Analysts lifted their price target on AbCellera Biologics by $1, citing recent bullish initiations and research that view the company’s profile as increasingly attractive relative to selected peers. Analyst Commentary Recent Street research on AbCellera Biologics highlights a mix of optimism and caution, with several firms updating their views and price targets in light of the company’s current positioning and peer comparisons.Analiz Makalesi • May 14
Earnings Update: Here's Why Analysts Just Lifted Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$10.14
AbCellera Biologics Inc. ( NASDAQ:ABCL ) investors will be delighted, with the company turning in some strong numbers...Anlatı Güncellemesi • May 06
ABCL: Platform And Partnerships Will Support Future Upside From GPCR Pipeline Progress
The analyst price target for AbCellera Biologics has shifted to $7.00, with analysts pointing to updated assumptions around the discount rate, revenue growth, profit margins, and a very large future P/E multiple. This view is supported by recent bullish Street coverage that frames the company as increasingly attractive relative to certain peers.Anlatı Güncellemesi • Apr 20
ABCL: Platform And Partnerships Will Support Future Upside Potential
Analysts have adjusted their price target on AbCellera Biologics to $7.00. The change reflects updated assumptions around revenue trends, profit margins, discount rates, and future P/E, supported by recent research that takes a bullish view on the stock.Anlatı Güncellemesi • Apr 06
ABCL: Menopause Phase 2 Progress Will Support Future Upside Potential
Analysts maintained their $7.00 price target for AbCellera Biologics, citing only very small adjustments to assumptions around discount rate, revenue trends, profit margin, and future P/E as the basis for keeping their overall valuation view steady. What's in the News AbCellera Biologics has started dosing patients in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause (Key Developments).Anlatı Güncellemesi • Mar 22
ABCL: Menopause Trial Progress Will Drive Future Share Price Upside
Analysts have trimmed their price targets on AbCellera Biologics to $7.00, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple that together point to a more cautious outlook on how quickly the business may scale. What's in the News First patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause (Key Developments).
Anlatı Güncellemesi • Mar 08
ABCL: Patent Settlement And Menopause Trial Will Support A Stronger Outlook
Analysts have lowered their price target on AbCellera Biologics from $15.88 to $12.00, reflecting updated views on fair value, revenue growth expectations, and future P/E assumptions. What's in the News The first patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause (Key Developments).Anlatı Güncellemesi • Feb 22
ABCL: Menopause Phase 2 Progress And Bruker Settlement Will Support Future Margins
Analysts have maintained their $9.83 price target on AbCellera Biologics, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E, which they view as collectively balanced at this stage. What's in the News AbCellera began dosing patients in the Phase 2 portion of its ongoing Phase 1/2 trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause.Anlatı Güncellemesi • Feb 08
ABCL: Clinical Progress And Royalty Deal Will Drive Future Share Price Upside
Analysts have reduced their price target on AbCellera Biologics, citing updated assumptions that incorporate higher expected revenue growth and profit margins, partially offset by a lower projected future P/E multiple. What's in the News First patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause.Anlatı Güncellemesi • Jan 24
ABCL: Phase 2 Menopause Trial Progress Will Support Future Profit Margins
Analysts have trimmed their price target on AbCellera Biologics to US$9.83, reflecting slightly lower discount rate assumptions, a modestly higher long term profit margin outlook, and a small adjustment to future P/E expectations. What's in the News First patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause.Anlatı Güncellemesi • Jan 08
ABCL: Patent Settlement Cash Flows Will Support A Stronger Future Outlook
Analysts have trimmed their implied fair value estimate for AbCellera Biologics from about US$17.00 to roughly US$15.88, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News AbCellera reached a global settlement and patent license agreement with Bruker Corporation, resolving ongoing patent litigation between the two companies (Key Developments).Anlatı Güncellemesi • Dec 14
ABCL: Higher Future Earnings Multiple Will Drive Strong Share Price Upside
Analysts have raised their price target on AbCellera Biologics by approximately 40 percent to reflect a higher fair value estimate of around 7 dollars per share. They cite expectations for modestly slower revenue growth, offset by improved profit margins and a richer future earnings multiple.Anlatı Güncellemesi • Nov 29
ABCL: Upcoming Clinical Trial Results Will Drive Future Profit Margins Higher
Analysts have adjusted their price target for AbCellera Biologics slightly downward from $10.20 to $9.83 per share. This change reflects more conservative expectations around future revenue growth and profit margins.Anlatı Güncellemesi • Nov 15
ABCL: Upcoming Clinical Trial Results Are Expected To Drive Profit Margins Higher
Analysts have raised their price target for AbCellera Biologics from $9.33 to $10.20 per share, citing improved profit margin forecasts even though revenue growth expectations have slightly moderated. What's in the News AbCellera Biologics has begun dosing the first participants in a Phase 1 clinical trial for ABCL575, an investigational antibody therapy aimed at treating moderate to severe atopic dermatitis with potential applications in other inflammatory and autoimmune conditions (Key Developments).Yeni Anlatı • May 18
Phase I Trials And Manufacturing Will Unlock Pipeline Potential
Transition to a clinical-stage biotech and internal programs could drive revenue through milestone fees and royalty payments from new molecules.Analiz Makalesi • May 15
Some Analysts Just Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates
The latest analyst coverage could presage a bad day for AbCellera Biologics Inc. ( NASDAQ:ABCL ), with the analysts...Seeking Alpha • Apr 17
AbCellera: Attractively Priced But A Catalyst Is Needed
Summary AbCellera's stock remains under pressure due to a shift towards internal development, which has reduced revenue and increased cash burn. AbCellera retains a large cash position, though, giving it a multi-year runway in which to demonstrate the merits of its platform. AbCellera's low enterprise value suggests that investors are either skeptical of the company's platform or ignoring its cash position. A more favorable macro environment and clinical success will likely be needed before AbCellera's stock moves meaningfully higher. Read the full article on Seeking AlphaSeeking Alpha • Mar 15
AbCellera: Burning Cash, Searching For 'Blockbusters'
Summary AbCellera's revenues plummeted post-COVID antiviral sales, leading to a significant net loss and an 85% drop in share price, now at ~$2.5. The company is pivoting to develop its own drug pipeline, with ABCL635 and ABCL575 in late-preclinical stages, targeting metabolic and inflammatory conditions. Financially, AbCellera has ~$840 million in liquidity, but its market cap is lower than its cash reserves, reflecting skepticism about its assets. The company's future hinges on successfully developing a blockbuster drug, with key catalysts not expected until 2026, making its current valuation a gamble. Read the full article on Seeking AlphaSeeking Alpha • Dec 23
AbCellera Biologics: Still A Concept Stock
Summary Today, we revisit a somewhat unique developmental company called AbCellera Biologics Inc. The company is moving towards focusing more on its wholly owned candidates off its platform rather than partnerships. The company has myriad very early-stage assets in development, and ABCL stock trades near the net cash on its balance sheet. An updated analysis around AbCellera Biologics follows in the paragraphs below. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 07
AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates
It's shaping up to be a tough period for AbCellera Biologics Inc. ( NASDAQ:ABCL ), which a week ago released some...Seeking Alpha • Oct 14
AbCellera: A Platform To Pipeline Transition
Summary AbCellera is shifting its focus from a platform biotech company to its internal drug pipeline. The company's lead asset, ABCL575, comes with a variety of risks, but in our opinion, has a value of a little over $1B and is derisked based on comparable therapeutics. AbCellera is on track to submit ABCL575 for clinical trials in Q22025, helping the market reset its valuation on the company closer to the value of the lead asset. Read the full article on Seeking AlphaSeeking Alpha • Aug 23
AbCellera: A Waiting Game With High Uncertainty
Summary AbCellera’s Q2 2024 revenue declined by 27% year-over-year to $7.3 million. The company’s net loss widened to $36.9 million due to increased R&D expenses. AbCellera’s cash and marketable securities totaled $697.6 million, with total liquidity exceeding $900 million. The number of molecules in clinical trials increased from nine to 14 within a year. A "hold" recommendation is maintained due to the speculative and high-risk nature of AbCellera’s business. Read the full article on Seeking AlphaAnaliz Makalesi • May 29
Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • May 16
AbCellera: Cash Providing Shelter From Market Weakness
Summary AbCellera Biologics is a drug discovery company focused on developing antibody therapies. While the company has developed a technology platform that is open to customers, the current market environment has accelerated its shift towards advancing internal programs. This move should allow the company to capture more value in the long run, but it is depressing revenue and increasing cash burn at the moment. AbCellera's large cash balance will safely see it through this current period, but financial conditions will likely need to ease for the stock to rebound. Read the full article on Seeking AlphaSeeking Alpha • Feb 28
AbCellera: Victim Of Its Own Success
Summary AbCellera Biologics has faced declining royalty revenues, along with decreased demand for R&D services due to the current financing environment. As a result, AbCellera is shifting focus towards advancing internal programs and partner programs with more potential downstream value. The combination of declining revenue and rising costs is pressuring the stock, even as the underlying business appears to be steadily progressing. This situation appears to have been exacerbated by the company's success during the pandemic leading to over-inflated investor expectations, and subsequently, disappointment. Read the full article on Seeking AlphaSeeking Alpha • Feb 13
AbCellera Biologics: Continuing To Expand Partnerships
Summary AbCellera Biologics Inc. saw a significant decline in revenue due to the end of the COVID-19 pandemic, but has a large cash hoard and continues to expand partnerships. Analyst firms continue to Buy/Outperform ratings on the stock, but the company's partner pipeline is primarily very early-stage candidates. An updated analysis around AbCellera Biologics follows in the paragraphs below. Read the full article on Seeking AlphaHissedar Getirileri
| ABCL | US Life Sciences | US Pazar | |
|---|---|---|---|
| 7D | -0.1% | 2.1% | 1.6% |
| 1Y | 101.2% | 16.5% | 18.6% |
Getiri vs. Endüstri: ABCL geçen yıl % 16.5 oranında getiri sağlayan US Life Sciences sektörünü aştı.
Getiri vs Piyasa: ABCL geçen yıl % 18.6 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| ABCL volatility | |
|---|---|
| ABCL Average Weekly Movement | 12.3% |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: ABCL hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: ABCL 'nin haftalık oynaklığı ( 12% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2012 | 562 | Carl Hansen | www.abcellera.com |
AbCellera Biologics Inc., Amerika Birleşik Devletleri’nde karşılanmamış tıbbi ihtiyaçların olduğu endikasyonlar için antikor bazlı ilaçların keşfi ve geliştirilmesi alanında faaliyet göstermektedir. Şirketin öncü ürünü, orta ila şiddetli vazomotor semptomların tedavisi için Faz 2 klinik deneme aşamasında olan, hormonal olmayan bir ilaç olan ABCL635’tir; diğeri ise atopik dermatit gibi T hücresi aracılı otoimmün hastalıkların tedavisi için Faz 1 klinik deneme aşamasında olan, tamamen insan kaynaklı ve yarı ömrü uzatılmış bir monoklonal antikor olan ABCL575'tir. Şirket, Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc ile T hücresi etkileşimli (TCE) çok spesifik antikorlar geliştirmek üzere bir araştırma işbirliği ve lisans anlaşması; ayrıca Viking Global Investors & ArrowMark Partners ve Biogen Inc. ile bir ortaklık anlaşması bulunmaktadır.
AbCellera Biologics Inc. Temel Bilgiler Özeti
| ABCL temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$2.48b |
| Kazançlar(TTM) | -US$143.96m |
| Gelir(TTM) | US$79.21m |
31.3x
P/S Oranı-17.2x
F/K OranıABCL aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| ABCL gelir tablosu (TTM) | |
|---|---|
| Gelir | US$79.21m |
| Gelir Maliyeti | US$191.00m |
| Brüt Kâr | -US$111.79m |
| Diğer Giderler | US$32.17m |
| Kazançlar | -US$143.96m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.47 |
| Brüt Marj | -141.13% |
| Net Kâr Marjı | -181.74% |
| Borç/Özkaynak Oranı | 0% |
ABCL uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/06 09:34 |
| Gün Sonu Hisse Fiyatı | 2026/07/02 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
AbCellera Biologics Inc. 13 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Robert Wasserman | Benchmark Company |
| Guyn Kim | BMO Capital Markets Equity Research |
| Evan Seigerman | BMO Capital Markets Equity Research |